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ABSTRACT
Patients with liver cirrhosis frequently have infection which can deteriorate further the already impaired
liver function. The most common form of infection in this particular patients are spontaneous bacterial
peritonitis, urinary tract infection, and respiratory infection. Causative organism mostly Gram negative
micro organism and originate from the gastrointestinal tract. The weaken of immune defense mechanism and
also the altered gastrointestinal tract motility can explained most of these infection. This paper will review
the bacterial infection in liver cirrhosis with some guidance in the management.
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INTRODUCTION
Liver cirrhosis is a diffuse chronic liver disease,
characterized by the formation of connective tissue and
nodules. It usually begins as inflammation, widespread
liver cell necrosis, formation of connective tissue and
nodule  regeneration. These things cause changes where
micro and macro circulation is no longer regular, due to
increased  connective tissue and the newly formed
nodule. In Indonesia, the most common form is
post-necrosis liver cirrhosis.1,2
Patients with cirrhosis have a high risk of bacterial
infection. This increased risk is correlated to the
severity of liver disease and the length of hospitalization.
The most frequent infection in cirrhotic patients is
spontaneous bacterial peritonitis (7-23%), respiratory
tract infection (6-10%), and urinary tract infection
(12-29%). However, in 1/3 to 1/2 of cases, the source of
infection and type of causative microorganism remains
unknown. The incidence of infection in hospitalized
patients is very high (30-50%). These bacterial
infections cause 25% of deaths in patients with liver
cirrhosis.5,6
ETIOLOGY
Escherichia coli is a commonly encountered microbe.
Negative-gram bacteria are more common than
positive-gram bacteria, as seen in the following table
(Table 1 and Table 2).7,8
 
Table 1. The Microorganism Pattern in Spontaneous 
Bacterial Peritonitis 
Organism Percentage 
E. coli 43 
K. pneumoniae 8 
Streptococcus pneumoniae 8 
Haemolytic streptococcus A 5 
Unclassified streptococcus 4 
Haemolytic streptococcus B 4 
Pseudomonas 2 
Staphylococcus aureus 2 
Others 16 
 
Table 2. The Microorganism Pattern in Bacteremia in 
Chronic Liver Disease 
Organism Percentage 
Staphylococcus 21 
E. coli 16 
Streptococcus pneumoniae 16 
Streptococcus viridans 5 
K. pneumoniae 5 
Proteus sp 5 
Pseudomonas - 
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IMMUNE REACTION DURING INFECTION
Everyone is exposed to various environmental
microbes that are ready to attack at any minute, but the
body constantly tries to defend itself. The body’s
reaction towards infection differs according to the type
and function of T lymphocytes, B cells that produce
antibodies, and the number of memory cells. In addition,
immune reactions also depend on the type and character
of the attacking microbe. On the other hand, various
microbes have different ways to avoid these reactions.3
For most infections, there is a balance between the
body’s defense system to fight off infection and the  ability
of the microorganism to avoid the body’s defense
system. Nevertheless, manifestations of infectious
diseases may occur if the host’s immune system is
unable to ward off infection.3,4
GENERAL IMMUNE RESPONSE AGAINST INFECTION
The Body Surface Defense Mechanism
The body’s defense mechanism towards infection can
be generally classified into two groups, the non-specific
immune response and the specific immune response.
Nevertheless, there is no clear cut line between these
two defenses systems, since they support each other.
The specific immune response can take place with the
assistance of  components of the non-specific immune
system, such as the macrophage, cytokine, and so on.
The natural or hereditary non-specific response includes
body surface barriers, secretion of certain substances
such as lysozime inside saliva, tears, and nasal secret.
Ig A and normal flora are external defense mechanisms,
along with phagocytes and complement. The barrier
mechanism and the external body defense system are
very effective. The skin and the epithelial or mucosal
surface are protective systems with a great ability to
limit the entrance of pathogenous microorganisms that
has effect on body tissues, except if the barrier function
is disturbed. On the other hand, pathogenous
microorganisms release certain substances on their
surface that allow them to adhere to epithelial or
mucosal surface. After a microorganism adheres on an
epithelial surface, it does not automatically penetrate the
cell, even though the microorganism tries to fight the
barrier, such as by releasing protease. Even though
various cells in the body are capable of phagocytosis,
the main cells that play a role in the non-specific
defense system are the mononuclear cells (monocytes
and macrophages), as well as polymorphonuclear cells
or granulocytes. These two kinds of cells are
phagocytes that originate from the granulocyte
hemopoietic stem cells that have granules containing
hydrolytic enzymes and lactoferin, which are bacteri-
cidal in character. Effective phagocytosis against initial
microbial invasion can prevent the development of
disease. Phagocytes also interact with complement and
the specific immune system. Destruction of microbes
occurs in the following levels: chemotaxis, the capture,
phagocytosis, the kill, and digestion. Chemotaxis is the
phagocytic movement to the site of infection as a
response against various factors such as bacterial
products and biochemical factors released during
complement activation. Destroyed or dead tissue could
also release chemotactic factors. Antibodies such as
complement (C3b) can increase phagocytosis
(opsonization). Phagocytes can more easily recognize
antigen bound by antibody to be destroyed.1,3,4,8
Systemic Defense Mechanism
The systemic defense mechanism can generally be
classified into the cellular immune response and humoral
immune response, also known as the specific immune
Immune Response in Liver Cirrhosis
Evaluation of immune response in patients with liver
cirrhosis includes immune response of the gastrointestinal
tract mucosa, immune response in the blood, and
immune response in ascites fluid.
Immune Response in the Gastrointestinal Tract Mucosa
Most microorganisms are unable to directly penetrate
the gastrointestinal tract. Hydrochloride acid in the gaster,
proteolytic enzymes and bile in the small intestines are
able to create an environment that could prevent
infection. Furthermore, lymphoid cells such as the pleyer
plaque and the lamina propria, which contain
lymphocytes, plasma cells, and macrophages according
to their function, stimulate mucosal immune response.3,4,5,6
Abnormalities found in the mucosal immune system
in patients with liver cirrhosis may take the form of small
intestine dysmotility, bacterial overgrowth, and blood
vessel congestion in portal hypertension.
Under normal intestinal peristalsis, gastric acid and
mucosal immunity acts to protect the intestines from
bacterial overgrowth. Intestinal peristalsis is
a significant inhibitor of bacterial colonization and
replication in the gastrointestinal tract. However,
bacteria growth in the small intestines causes
production short-chain fatty acids (SCFA), due to
carbohydrate fermentation by the bacteria. SCFA
stimulates proliferation of epithelial cells in the small
intestines, causing pseudo-obstruction of the bowel, and
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In addition to reduced phagocytic ability, there is also
reduced blood complement level. This complement is a
normally inactive molecule, which could be activated by
certain substances, such as (bacterial) antigen or
immune complex. Such activation produces mediators
such as C3a, C5a, and C3b, which have active biologic
characteristics. C5a helps increase antibody formation
and C3b aids the process of opsonization. Complements
are synthesized by hepatocytes, and produced by
macrophages, gastrointestinal epithelial tissue, and
monocytes.4,5,9,16
Immune Response in Ascites Fluid
Ascites is a collection of fluid in the peritoneal cavity.
In cases of liver cirrhosis, ascites indicates a poor
prognosis. SBP is a serious complication in patients with
liver cirrhosis and ascites. SBP is usually associated with
several body defense mechanisms, such as reduced
phagocytic RES activity, leukocyte dysfunction, reduced
serum complement and low bactericidal activity in
ascites fluid. Another factor that is believed to influence
the immune capability of ascites fluid in eradicating
microbes is reduced protein level. If the volume of
ascites fluid is large, the protein level is reduced.
Reduced protein content in ascites fluid is believed to be
able to reduce bactericidal activity, increasing the risk
for SBP. The number of bacteria in ascites fluid is only
approximately 1-2 bacteria/cc ascites fluid. Thus, if the
bactericidal activity in the ascites fluid functions correctly,
the bacteria can be eradicated. If there is diuresis, the
protein content in the fluid will be increased. It has long
been known that malnutrition reduces immune response
ability. Such reduced immune response in cases of
malnutrition could occur due to reduced albumin level.
Serum albumin level influences serum complement level.
Several studies also demonstrate that malnutrition is
related with bacterial translocation from the intestinal
lumen.1,2,6,9,14
is believed to cause bowel dysmotility. When bowel
motility and transit is disturbed, bacteria aggregates. Such
bowel transit failure has been proven in rats with portal
hypertension. In the most recent study on alcoholic liver
cirrhosis, patients with bacterial overgrowth in the small
intestines develop a higher rate of spontaneous bacterial
peritonitis (SBP). This condition was proven from the
fact that bacterial growth was higher in patients with
liver cirrhosis and SBP than in patients with liver
cirrhosis without history of SBP. Bowel dysmotility is
more severe in patients with liver cirrhosis and history
of SBP. This could be more clearly illustrated from the
fact that selective intestinal decontamination with
antibiotics could prevent recurrent SBP. Thus,
disturbance of intestinal motility causes bacterial over-
growth that could explain the development of recurrent
SBP in patients with liver cirrhosis.6-11
The gastrointestinal mucosa acts as a barrier against
bacteria, toxins, and other bacterial products in the
lumen. This barrier is important in preventing bacterial
translocation from the intestines through the mesenteric
lymph nodes and entering the systemic circulation.
Deitch formulated three mechanisms of bacterial
translocation, which are as follows: bacterial overgrowth,
failure of the body’s defense system, and destruction of
intestinal mucosa. Bacterial translocation could also
occur due to one or more of these mechanisms under
portal hypertension or gastroenteropathy congestion,
causing failure of acid secretion and reduced mucosal
resistance, making it more vulnerable to destruction by
alcohol or bile salts, and the mucosa may suffer from
ischemia. Ischemic mucosa facilitates bacterial
translocation.9-13
Immune Response in the Blood
Patients with liver cirrhosis and bacterial infection
suffer from prolonged bacteremia compared to those with
liver cirrhosis alone. This could be due to reduced
phagocytic activity of the reticuloendothelial system
(RES), reduced complement level and reduced
leukocyte chemotaxis. Reduced RES activity plays the
main role in the development of bacterial infection in
patients with liver cirrhosis. The liver RES consists of
Kupffer cells and sinusoidal cells. Reduced liver RES
activity is compensated by the activity of RES of the
spleen and vertebrae. The mechanism of failure of RES
phagocytic activity is correlated with intra-hepatic blood
flow shunting due to portal hypertension, causing
bacteria to elude phagocytosis by liver RES. The
number of bacteria in systemic circulation and ascites
are thus increased.6,7,12,16
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Cytokines in Liver Cirrhosis
Cytokine is a peptide mediator that could reduce or
increase immune response, inflammation, and the body’s
response to repair damaged tissue. Cytokines can
induce other cytokines or cooperate with other cytokines
to stimulate the cell (synergism). On the other hand,
cytokines could also prevent the production of other
cytokines (antagonism). In general, cytokines can be
classified into Interleukin (IL), Interferon (IFN), Tumor
Necrosis Factor (TNF), and chemokine (IL-8). Cytokines
that have been studied in bacterial infection in patient
with liver cirrhosis are IL-1 β, IL-6, IL-8, IFN γ, and
TNF α.6
Infection results in the release of endogenous
mediators that are responsible for inflammatory response,
even though such response is aimed towards combating
infection, it can also disturb the body’s chemo-dynamic
and metabolic state. Cytokines, especially TNF α, IL-1
β, and IL-6 are the most important sepsis mediators in
patients with liver cirrhosis. In addition, intraperitoneal
release of IL-6 is significantly high in patients with
cirrhosis and ascites complicated by spontaneous
bacterial peritonitis (SBP). The most recent study
demonstrated a positive relationship between the
circulatory level of TNF α and IL-6 with mortality in
alcoholic hepatitis patients.6-8.14.18.19
All data demonstrate that the inflammatory response
against infection determined from plasma cytokine
levels and ascites fluid increases in patients with
cirrhosis, where cytokine can be an important
prognostic factor. Renal insufficiency (RI) in SBP
(SBP-RI) is common in patients with cirrhosis accom-
panied by ascites, and is an important predictor of the
patient’s survival. The connection between the develop-
ment of SBP-RI and mortality during hospitalization, and
the   degree of inflammatory response induced by
intraabdominal infection, is through the release of
intraperitoneal cytokines into the systemic circulation
result in a circulation dysfunction and renal insufficiency,
thus leading to death.
Positive culture in 50-85% of SBP cases and cytokine
in ascites fluid in SBP may originate from  peritoneal
macrophages and mesothelial cells. The concentration
of IL-6 and TNF α in ascites fluid is far higher than the
plasma level. On the other hand, there is a direct
relationship between cytokine level in ascites fluid and
that in plasma, indicating a cytokine level approximately
the same in the blood and intraabdomen. This finding
demonstrates a rapid drop of cytokine concentration in
ascites fluid and plasma after administration of
antibiotics, as seen 48 hours after the administration of
cefotaxim, where the cytokine levels in all patients that
responded were reduced. Patients with SBP and
positive culture containing gram-negative bacteria
demonstrated a higher cytokine level in plasma and
ascites fluid, as well as increased PMN cell count. This
demonstrates that in SBP, intraabdominal inflammatory
response can be estimated from PMN concentration and
cytokine level in ascites fluid depends on the
concentration and type of causative organism. When
correlated, SBP-RI demonstrated similarly high
concentrations of PMN in ascites fluid and plasma, as
well as high cytokine levels in ascites fluid compared to
patients without renal insufficiency. Renal insufficiency
can occur spontaneously in patients with cirrhosis and
ascites. This is believed to be related to arterial
vasodilatation. Hepatorenal syndrome is an extreme
condition that occurs during this circulatory dysfunction.
Nitric oxide is believed to play a role in this abnormality,
because cytokine stimulates vascular tissue to produce
nitric oxide.9,15,19,20,21
The Effect of Infection on Esophageal Variceal
Bleeding
Variceal bleeding is a fatal complication of liver
cirrhosis, and bleeding cannot be predicted. Bacterial
infection in patients with variceal bleeding may be the
main trigger of bleeding. Variceal dilatation and increased
pressure of variceal wall causes release of endotoxins
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Figure 1. Scheme of Respons in Liver Cirrhosis
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into the systemic circulation during the episode of
bacterial infection. Afterwards, portal pressure increases
through endothelin induction, producing an end result of
cyclo-oxygenase, which causes vasoconstriction. In
addition, endotoxin stimulated nitric oxide and
prostacyclin. This endothel-produced prostacyclin
inhibits platelet aggregation. It could thus be concluded
that a combination of these two effects could accelerate
variceal bleeding. Varices and variceal bleeding is a
direct effect of portal hypertension that occurs in chronic
liver disease. Continuous bleeding should receive
immediate care, and recurrent bleeding at initial stages
could increase the morbidity and mortality rate.1,3,4,10,12,16
Variceal bleeding is a common and severe
complication in cirrhotic patients, even with various new
therapies such as pharmacotherapy, variceal ligation, and
transjugular hepatic portosystemic shunt (TIPS).
Nevertheless, the mortality rate remains high due to
inability to control bleeding. Sixty percent of cases of
bacterial infection that often occurs in cirrhotic patients
with gastrointestinal bleeding significantly influences
mortality. Research demonstrates that bacterial
infection can be prevented by administration of
antibiotics. However, we must also be aware that there
are differences in the evidence of infection with
administration of antibiotics, since bacterial infection in
cirrhotic patients cannot be proved microbiologically.
Evidence of infection characterized by fever,
leukocytosis, or clinical symptoms of pulmonary
infection, urinary tract infection, or other infections is a
prognostic factor for failure to control bleeding. There is
a strong correlation between gastrointestinal bleeding and
bacterial infection, which can be caused by diagnostic
procedures and invasive therapy, increased bowel
bacteria translocation, disturbance of the
reticuloendothelial system, complement factor deficiency,
which can be a predisposing factor of bacteremia in
cirrhotic patients. Vice versa, there are data that
supports the role of infection in the development of
gastrointestinal bleeding. During bacterial infection, there
is a release of endotoxin into the systemic circulation. In
cirrhotic patients, the reticuloendothelial system fails to
destroy the endotoxin. Thus, inflammatory mediators
such as cytokine, nitric oxide, platelet activating factor
and leukotriene are activated. These mediators destroy
the structure and function of the gastrointestinal tract,
characterized by vascular dilatation, bleeding, and
necrosis, and several abnormal signs such as platelet
dysfunction, reactivation of coagulant and fibrinolytic
system, and thus gastrointestinal bleeding is no longer a
rare condition in severe bacterial infection. This
hypothesis is supported by the fact that most infection in
cirrhotic patients with gastrointestinal bleeding were
diagnosed on the first day. Thus,  therapeutic or
prophylaxis antibiotics should be administered
immediately during acute bleeding time, thus reducing
the frequency of bacterial infection.2,9,11,14,24,26
The Effect of Endotoxins
Endotoxin is a lipopolysaccharide that makes up the
outer wall of the negative-gram bacteria. In vivo,
endotoxin stimulates the body defense response
mechanism. In this mechanism, endotoxin acts as a
trigger,  stimulating the production of several mediators.
In patients with chronic liver disease, high
concentrations of endotoxin in the portal and systemic
circulation are found due to increased endotoxin
translocation from the bowel to the portal circulation.
Disturbed phagocyte function of the reticuloendothelial
system as well as portosystemic shunting help endotoxin
reach the systemic circulation. Thus, the concentration
of endotoxin continuously increases progressively
according to the severity of liver dysfunction. During
the episode of  bacterial infection, the concentration of
endotoxin released into the systemic circulation increases.
Approximately 35-66% of cirrhotic patients with
bacterial infection suffer from variceal bleeding. Most
of these infections were diagnosed during the first days
of treatment. Spontaneous bacterial peritonitis often
occurs prior to variceal bleeding. Secondary endotoxemia
from bacterial infection can also induce bleeding. Thus,
it can be concluded that endotoxin influences the
endotoxin effect through the synthesis of endothelin and
nitric oxide. The cascade mechanism activated to
produce mediators closely related to endotoxin is the
complement system, clotting system, and hemostasis, as
well as cytokine pro-inflammatory mediators. Septic
shock in bacterial sepsis does not occur solely due to
endotoxin, but is a direct effect of the simultaneous
interaction  between microbes, toxins, and endogenous
mediators (cytokine). Liver is the chief target organ that
functions to eliminate endotoxin from the circulation
(>80%). In the liver, endotoxin will be detoxified by
Kupffer cells and parenchyme tissue.14,16,17,20,23
The Effect of Endothelin
Endothelin was first identified in 1988, belonging from
the “21-amino acid peptide” family, consisting of 3
structures: endothelin (ET-1), ET-2, and ET-3, with two
different pairs of receptors, the endothelin A and
endothelin B receptors. Endothelin receptors can be found
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in all types of liver cells, the stellate, as well as
endothelial cells, Kupffer cells, and hepatocytes, even
though examination of liver cells demonstrate a more
significant number of endothelin receptor on the stellate.
The liver stellate cell is activated during liver destruction
until the liver is contracted. Thus, this cell plays an
important role in the therapy of intrahepatic portal
hypertension in liver cirrhosis. In cirrhotic patients, the
concentration of endothelin (especially endothelin-1) is
increased in the splancnic circulation, followed by
increased activation of liver stellate cells. What is most
important is that endothelin causes contraction of
stellate cells, causing increased portal pressure, and
medication using the endothelin receptor antagonist
Bosentan and TAK-044 can significantly reduce portal
pressure. Moller has proved that the release of
endothelin-1 by the hepatosplancnic system has a
positive correlation with portal hypertension in patients
with liver cirrhosis. In   laboratory animals, it has been
demonstrated that after exposure to endotoxin, the level
of endothelin-1 in liver sinusoid endothelial cells and
plasma endothelin concentration increases ten folds.
Pannen stated that administration of lipopolysaccharide
infusion increases portal flow resistance by inducing
endothelin, and this effect is inhibited by administration
of bosentan. In  addition, Yamamoto found that therapy
using bosentan and cyclooxygenase inhibitors such as
indomethasin can inhibit increased portal vein pressure.
During endotoxemia, cyclooxygenase products such as
thromboxane A2 and prostaglandin are vasoconstriction
mediators that increase portal pressure. Endothelin also
induces variceal bleeding through the endothelin effect,
where platelet aggregation is inhibited by prostacyclin, a
strong platelet aggregation inhibitor. Prostacyclin
increases in cirrhotic patients during endotoxemia, by
direct action of endotoxin. In addition to inducing
endothelin and cyclooxygenase, endotoxin also induces
nitric oxides, which inhibit platelet aggregation.
A combination of these factors accelerate variceal
bleeding.4,6,20,23
MANAGEMENT
Prevention
In patients with liver cirrhosis who suffer from
gastrointestinal bleeding, prophylactic antibiotics can
reduce the incidence of infection, but does not
demonstrate increased survival rate.
Success in selective intestinal decontamination with
norfloxacin for prevention of bacterial infection in liver
cirrhosis with gastrointestinal bleeding has been
demonstrated in several studies. Administration of
400 mg of norfloxacin twice daily for 7 days significantly
reduces the incidence of bacterial infection such as SBP
and urinary tract infection.
Aerobic gram-negative bacteria are the most
common cause of such bacterial infection, and culture
performed on patients with infection for the first 10 days
of hospitalization. Initial studies demonstrate bacterial
infection in 22% of patients in the first 48 hours after
hospitalization. For 7 to 14 days after the initial time of
bleeding, the incidence of bacterial infection reaches
35-66%. In addition, infection is closely related to the
prognosis of cirrhotic patients suffering from bleeding.
A study demonstrated that bacterial infection is the main
causative factor of recurrent bleeding in 7 days. Enteric
bacteria are the most common cause of infection in
patients with liver cirrhosis. Administration of
non-absorbable antibiotics reduces the incidence of
infection in patients with liver cirrhosis suffering from
bleeding. Several studies demonstrate that
administration of  prophylactic antibiotics can reduce the
incidence of  infection.
Quinolone, amoxycillin plus clavulanic acid, and
non-absorbable antibiotics are possible antibiotics for
prophylaxis. Even though therapy seems to differ, their
capability in preventing infection has been clearly
demonstrated. These medications may be administered
for 5 to 10 days.
However, a study by Pauwel demonstrated that
administration of prophylactic antibiotics should only be
considered in patients with a high risk for infection,
Child-pugh’s class-C or that with bleeding.
Norfloxacin is a quinolone that produces Selective
Intestinal Decontamination (SID) that can inhibit
gram-negative aerobic bowel flora, but can maintain
anaerobic flora and resistance to colonization in the
gastrointestinal tract. Norfloxacin reduces the incidence
of infection due to negative gram-bacteria in patients
with granulocytopenia, and is useful to prevent
recurrent SBP in patients with liver cirrhosis
hospitalized with ascites. Rimola found reduced incidence
of enteric bacterial infection for the initial 10 days of
hospitalization in patients who received non-absorbable
oral antibiotics.
The ability of norfloxacin in preventing bacterial
infection in patients with liver cirrhosis and
gastrointestinal bleeding can be administered orally or
via NGT with a dose of 400 mg 2 times/daily for 7 days,
and should be administered as soon as possible. It is also
said that   prophylactic treatment with norfloxacin may
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be administered for over 6 months without side effects
and without causing bacterial resistance. Because
almost 25% of deaths in patients with liver cirrhosis are
directly caused by infection, reduction of the incidence
of infection should reduce mortality.
Even though gram-negative bacteria are commonly
found, Rimola found a high incidence of infection caused
by other types of bacteria, especially negative gram
cocci. This could occur due to invasive procedures
performed on theses patients, since infection related to
invasive procedures are often caused by gram-positive
cocci.1,2,8,10,24,25
Even though usage of prophylactic antibiotics is
recommended, long-term administration could increase
the incidence of resistance of gram-negative bacilli
towards Quinolone. Increased bacterial resistance against
prophylactic antibiotics can cause more severe infection
than that in patients who have never received
prophylactic treatment. Resistance to β lactam has also
been observed, since it has been commonly used for the
treatment of infection. This makes the treatment of
infection in liver cirrhosis more difficult. It must be noted
that infection due to norfloxacin-resistant E-coli can  occur
only after several days of prophylactic treatment.
Development of multi-resistant bacteria (resistance to
antibiotics other than norfloxacin) should caution the use
of prophylactic antibiotics. Analysis of
norfloxacin-resistant E. coli demonstrated
cross-resistance against quinolone and other quinolones
such as ciprofloxacine and ofloxacine. This is related to
mutation that influences the target quinolone DNA-gyrase
and/or topoisomerase that is the most important
mechanism in the development of quinolone resistance.
Increased infection has been observed due to
norfloxacin-resistant E-coli in cirrhotic patients who have
received other prophylactic antibiotics, trimethropin/
sulfamethoxazole.6,10,13,17,26
Therapy with Systemic Antibiotics
Acute infection, especially bacteremia and infection
of ascites fluid, is the most common complication in
patients with liver cirrhosis, most commonly caused by
microorganism in the gastrointestinal tract. High risks of
infection during gastrointestinal bleeding is caused by
endoscopic and resuscitation procedures as well as
translocation of bowel bacteria. Risks of bacterial
infection are associated with the severity of liver
disease. The frequency of bacteremia during endoscopic
sclerotherapy can reach 50% with the incidence of
bleeding. Endoscopic hematemesis of the upper
gastrointestinal tract or insertion of the nasogastric tube
could also induce pneumonia.
Short-term mortality in infected patients associated
with liver failure is quite high.
There have been study reports that administration of
oral antibiotics in patients with liver cirrhosis during
gastrointestinal bleeding demonstrates reduced incidence
of bacterial infection due to enterobacteria. The latest
studies even demonstrate the efficacy of oral norloxacin
in preventing infection by enterobacteria without
causing resistance. However, certain therapy cannot be
administered during bleeding, and cannot prevent
extra-digestive infection.
Systemic antibiotic treatment (SAT) can prevent
infection and even reduce mortality. In addition, SAT has
the ability to eradicate positive-gram and anaerobic
bacteria found from endoscopy during active bleeding.
Associated reduction of infection with positive-gram
bacteria, especially streptococcus and haemophilus
influenzae is found from studies using
amoxycillin-clavulanic acid (ACA) and ofloxacine
(OFL). Thus, it can be concluded that SAT using
ofloxacine and ACA bolus prior to endoscopic proce-
dure can prevent infection in cirrhotic patients with gas-
trointestinal bleeding, where administration of systemic
antibiotics is very simple during gastrointestinal bleeding
compared to in oral decontamination.8,12,27
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